<DOC>
	<DOC>NCT02052999</DOC>
	<brief_summary>The objective of this study is to determine the efficacy and safety of PAC-14028 1% cream of Amorepacific Corporation in patients with erythema-telangiectatic or papulopustular rosacea</brief_summary>
	<brief_title>Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<criteria>Male and female patients at the age of 20 to 65 years old Clinical diagnosis of erythematotelangiectatic or papulopustular rosacea according to National Rosacea Committee Expert Society with Erythema severity ≥ 1 Telangiectasia severity ≥ 1 At least 3 papules or pustules in facial region IGA score ≥ 2 Voluntarily signed written informed consent forms for study participation Patients who are unable to be diagnosed or evaluated for rosacea due to tattoo or scar in the facial area Patients who are unable to be diagnosed or evaluated for rosacea due to excess hair(e.g., mustache, beard, whiskers etc.) in the facial area Patients who are sensitive to the drug or vehicle Previous administration of oral retinoid or vitamin A(≥10,000 units/day) within 6 months prior to visit 1 Previous use of estrogen or oral contraceptives within 3 months prior to visit 1 Previous use of topical retinoids or oral antibiotics (e.g., tetracycline, tetracycline derivatives, erythromycin, erythromycin derivatives, sulfamethoxazole, trimethoprim) or oral steroid for the treatment of facial rosacea within 1 month prior to visit 1 Previous use of topical steroid or topical antibiotics, topical treatment for rosacea(e.g., metronidazole, azelaic acid) within 2 weeks prior to visit 1 Presently undergoing anticoagulant therapies History of hematologic disease Ocularonly, Phymatous rosacea, or papulopustular rosacea patients who require systemic antibiotics History of laser treatment for rosacea within 6 weeks prior to visit 1 Alcoholic or drug abuse patients Patients who are treated with prohibited concomitant drugs or considered to inevitably require treatment with prohibited concomitant drugs during the study period Renal function impairment with creatinine level higher than twice of maximum normal range Hepatic function impairment with AST/ALT higher than twice of maximum normal range Pregnant and lactating woman, woman with childbirth potential(should have negative pregnancy test at the baseline visit of the study) Participation in another clinical study within 1 month prior to screening Patients considered ineligible for study participation by the principal investigator or subinvestigator for other reasons; rosacea due to other medical (liver disease, renal failure, etc.), psychotic, or neuropathic causes rather than as a skin disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>